IGC Pharma (NYSE American: IGC) today announced that ClinCloud, a clinical research facility in Florida, has dosed its first patient as part of IGC’s ongoing phase 2b trial. The company is currently conducting the trial at twelve sites in the U.S. and Canada with IGC-AD1, a combination medicine with a CB1 receptor partial agonist with … Continue reading InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Activates ClinCloud in Phase 2b Alzheimer’s Trial